Literature DB >> 11431059

Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents.

C Fuschillo1, S La Pia, F Campana, A Pinto, L De Simone.   

Abstract

Entities:  

Year:  2001        PMID： 11431059     DOI： 10.1016/s0167-4943(01)00134-0

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr Suppl        ISSN： 0924-7947


× No keyword cloud information.
  6 in total

1.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Rivastigmine for Alzheimer's disease.

Authors:  Jacqueline S Birks; Lee Yee Chong; John Grimley Evans
Journal:  Cochrane Database Syst Rev       Date:  2015-09-22

3.  Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.

Authors:  Douglas W Scharre; Francis Vekeman; Patrick Lefebvre; Nikita Mody-Patel; Kristijan H Kahler; Mei Sheng Duh
Journal:  Drugs Aging       Date:  2010-11-01       Impact factor: 3.923

Review 4.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 5.  Donepezil for dementia due to Alzheimer's disease.

Authors:  Jacqueline S Birks; Richard J Harvey
Journal:  Cochrane Database Syst Rev       Date:  2018-06-18

6.  Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

Authors:  Roberta Annicchiarico; Alessia Federici; Carla Pettenati; Carlo Caltagirone
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.